How the End of the Public Health Emergency Reshaped Everyday Life
The May 2023 ending of the COVID-19 public health emergency was a quiet milestone. Most readers had moved on long before, but regulatory paperwork took time. Federal agencies in Washington, insurers, and hospitals spent the months leading up to the deadline unwinding temporary rules on testing, vaccines, treatment, and data reporting. The transition looked less like a clean break and more like a slow handover from crisis footing to a permanent but uneasy normal.
For Australians following from Sydney, Melbourne, Brisbane, or Perth, the American transition carried familiar echoes. Australia's National Cabinet had wound back most domestic restrictions earlier, while the Therapeutic Goods Administration and the Department of Health and Aged Care kept working through the residue. Both countries now share the same post-emergency questions: who pays for vaccines and antivirals, how to keep surveillance reliable, how to support people with persistent symptoms, and how to harden the system against the next pathogen.
The mechanics of ending an emergency declaration
Emergency declarations unlock funding streams, legal powers, and regulatory flexibilities ordinary statutes do not allow. In the United States, the Public Health Service Act gave the Secretary of Health and Human Services authority to declare a public health emergency, activating Title II waivers, easing cross-state licensing, and allowing Medicare to reimburse telehealth at parity with in-person visits. When the declaration lapsed, those powers lapsed with it, leaving agencies to either bake temporary rules into permanent law or let them quietly expire.
Australia operates differently. Emergency powers are largely state-based, layered with federal levers such as the Biosecurity Act and the National Health Security Agreement. The Australian Health Protection Principal Committee, made up of chief health officers from each state and territory, advised on the response. The Howard Springs quarantine facility in the Northern Territory was progressively decommissioned. Federal and state public health acts remained, but most bespoke pandemic orders disappeared alongside the political appetite for them.
A post-emergency comparison
How each country handled the unwinding reveals something about its health system. The following comparison sets out where the United States, Australia, and the United Kingdom landed on five key policy areas after their respective emergencies ended.
| Area | United States | Australia | United Kingdom |
|---|---|---|---|
| COVID-19 vaccines | Commercial market; coverage via Medicare, Medicaid, or private insurance | Funded via the National Immunisation Program for priority groups | Provided free via the NHS during targeted campaigns |
| PCR and rapid antigen tests | No longer federally funded; private purchase or insurance | Limited free supply for high-risk groups; widespread retail and pharmacy access | Phased out for the general public |
| Antiviral medications | Medicare and insurance coverage; manufacturer assistance | Listed on the Pharmaceutical Benefits Scheme with patient co-payment | Prescribed through the NHS |
| Telehealth flexibilities | Mixed; some Medicare flexibilities made permanent | MBS items retained and broadened | Largely kept in place |
| Mandatory lab and case reporting | Switched from daily mandatory to voluntary, then largely ceased | Continued via state notifiable diseases schedules | Reduced to weekly summaries |
A clear pattern runs through the comparison. The United States concentrated its freest access during the emergency, then shifted most services to a commercial market. Australia and the United Kingdom leaned on universal coverage to maintain vaccine and antiviral access. Each approach carries risks, from outbreaks among under-vaccinated groups to surveillance blind spots when reporting systems thin out.
Insurance, telehealth, and the new cost map
In the United States, the post-emergency world returned to the familiar terrain of deductibles, copays, and prior authorisations. Insurers were no longer required to cover eight rapid antigen tests per month, and antivirals such as Paxlovid moved from government stock back to commercial distribution. For Medicare beneficiaries, antiviral coverage continued only after clinicians documented a high risk of progression. The shift reshaped pharmacy counters in Los Angeles and Houston, where free test giveaways had been a fixture for more than a year.
Australia's Pharmaceutical Benefits Scheme absorbed the main cost burden. Both Lagevrio and Paxlovid were listed on the PBS in 2023, so patients paid a standard concessional or general co-payment rather than the unsubsidised price of more than a thousand dollars a course. Telehealth, once a niche service, became embedded in routine care. Services delivered by video or phone doubled during the pandemic and have stayed elevated in Sydney, Adelaide, and regional centres such as Toowoomba. Most MBS items for telehealth are now permanent.
Vaccination programs after the emergency
Booster uptake has lagged in wealthy countries. In the United States, the Bridge Access Programme delivered free boosters through pharmacies, doctors, and community clinics through December 2023, after which manufacturers set list prices and insurers negotiated rebates. The CDC's Advisory Committee on Immunisation Practices still recommends annual boosters for older adults and the immunocompromised, though uptake has fallen well short of the 2022 peak. Influenza and RSV vaccination now compete for attention.
Australia's booster story is more encouraging. Top-tier OECD coverage for the primary series sat in New South Wales and Western Australia, although gaps persisted in some Indigenous communities. Booster updates now move through the Australian Technical Advisory Group on Immunisation, then the Department of Health and Aged Care, and into the National Immunisation Program. Pharmacists in Queensland and Victoria deliver most seasonal boosters, a scope change that survived the emergency. RSV vaccines for older adults are now under review, marking a shift from crisis to routine immunisation.
Long COVID and disability recognition
Long COVID remains the most stubborn legacy of the pandemic and the one least tied to the emergency clock. In the United States, the Department of Health and Human Services released a national research action plan before the formal end, coordinating studies across the National Institutes of Health, the Veterans Health Administration, and academic centres. Recognition under the Americans with Disabilities Act has been clarified for people whose symptoms substantially limit major life activities, although proving that threshold remains hard for many claimants.
In Australia, the Australian Bureau of Statistics estimated that hundreds of thousands of adults had experienced persistent symptoms after a positive test, with fatigue, brain fog, and breathlessness the most common complaints. The federal government funded dedicated long COVID clinics in New South Wales, Victoria, and Queensland, although several wound down when emergency funding ended. The Pharmaceutical Benefits Scheme does not list a treatment for long COVID, so care relies on existing chronic disease pathways. Some advocates have pushed for a dedicated Medicare item number, similar to Chronic Disease Management plans GPs already use for diabetes.
Australia's quiet pivot from pandemic mode
Australia carried unusual baggage into the post-emergency period. Melbourne's cumulative lockdown days exceeded those of almost any other Western city, and that experience continues to colour political debates in Victoria about the powers of the Chief Health Officer and the transparency of pandemic orders. Aged care, which absorbed the worst of Australia's 2022 outbreaks, has been rebuilt around infection control leads and mandatory staff vaccination, although a Royal Commission-style inquiry remains on several advocacy wishlists. Sydney's Opera House sails lit up in blue to mark vaccination milestones, soft propaganda the federal Opposition still invokes against new biosecurity powers.
The economic backdrop shapes the pivot. Higher borrowing costs and a tighter labour market have squeezed state health budgets, slowing recruitment of nurses in Canberra and Darwin. New private virtual care providers, born during the pandemic, now compete with established telehealth platforms for the same MBS rebates. The Australian Health Protection Principal Committee still meets when needed, but has stepped out of daily news cycles, and the public-facing data dashboards curated by the Department of Health have been retired in favour of monthly summaries hosted by state agencies.
Lessons carried forward
Two lessons have emerged from the unwinding. Funding sources matter. Programs that relied on emergency appropriations were the quickest to lose steam, while services channelled through existing statutory frameworks, including PBS listings, NIP schedules, and MBS items, survived more cleanly. Surveillance also matters. Daily mandatory reporting systems cannot step down to voluntary sample testing without losing signal. Reduced genomic sequencing throughput in the United States and Australia's quiet shift to state-level reporting both show how quickly data infrastructure degrades when attention moves elsewhere.
Policy experiments with mixed results are likely to be revisited. School-based vaccine clinics, at-home antiviral delivery, and pharmacists acting as primary immunisers all proved their worth under pressure and have largely been retained. Makeshift field hospitals and purpose-built quarantine facilities remain costly empty structures that governments are reluctant to maintain. The next pandemic will almost certainly be detected faster, but whether the response machinery can be reassembled in time will depend on choices made now.
Stay informed. WorldIndependant covers the policies, court rulings, and political decisions shaping the post-pandemic world, and our daily briefings land in your inbox. Subscribe to the newsletter and follow our coverage of US politics, the UK, Europe, and the Asia-Pacific region to see how the lessons of the COVID era continue to play out across borders.